Michael Kinch – författare

The introduction of new medicines has dramatically improved the quantity and quality of individual and public health while contributing trillions of dollars to the global economy. In spite of these past successes — and indeed because of them — our ability to deliver new medicines may be quickly coming to an end. Moving from the beginning of the twentieth century to the present, A Prescription for Change reveals how changing business strategies combined with scientific hubris have altered the way new medicines are discovered, with dire implications for both health and the economy.To explain how we have arrived at this pivotal moment, Michael Kinch recounts the history of pharmaceutical and biotechnological advances in the twentieth century. Kinch relates stories of the individuals and organizations that built the modern infrastructure that supports the development of innovative new medicines. He shows that an accelerating cycle of acquisition and downsizing is cannibalizing that infrastructure Kinch demonstrates the dismantling of the pharmaceutical and biotechnological research and development enterprises could also provide opportunities to innovate new models that sustain and expand the introduction of newer and better breakthrough medicines in the years to come.

The introduction of new medicines has dramatically improved the quantity and quality of individual and public health while contributing trillions of dollars to the global economy. In spite of these past successes--and indeed because of them--our ability to deliver new medicines may be quickly coming to an end. Moving from the beginning of the twentieth century to the present, A Prescription for Change reveals how changing business strategies combined with scientific hubris have altered the way new medicines are discovered, with dire implications for both health and the economy.To explain how we have arrived at this pivotal moment, Michael Kinch recounts the history of pharmaceutical and biotechnological advances in the twentieth century. Kinch relates stories of the individuals and organizations that built the modern infrastructure that supports the development of innovative new medicines. He shows that an accelerating cycle of acquisition and downsizing is cannibalizing that infrastructure Kinch demonstrates the dismantling of the pharmaceutical and biotechnological research and development enterprises could also provide opportunities to innovate new models that sustain and expand the introduction of newer and better breakthrough medicines in the years to come.

Diffraction and background-limited operation at room temperature is the ultimate goal of the infrared physicist. The achievement of this goal is strongly dependent on the hybridization technology utilized in bonding the IR focal plane array to the Si ROIC. To this end, this book describes a disruptive architecture in the field of hybridization known as the vertically integrated photodiode. This technology, as applied specifically to HgCdTe, is described in detail by the author. However, it can in principle be applied to any IR semiconducting material system, provided suitable dry etch and passivation technologies exist. The limitations of the many current and varied IR architectures are discussed with regard to diffraction and background-limited performance as a function of operating temperature. Shockley–Read–Hall lifetime is found to be a major factor in these considerations, for which HgCdTe has no IR equal. However, a number of scientific and engineering challenges remain within the HgCdTe materials system before ultimate performance can be achieved. A discussion of those challenges, together with possible outcomes, constitutes the basis of this book.

From "pharma bros" to everday household budgets, just how did the pharmaceutical industry betray its own history—and how can it return to its tradition of care?It’s an unfortunate and life-threatening fact: one in five Americans has skipped vital prescriptions simply because of the cost. These choices are being made even though we have reached a point in the conveyance of medical options where cancers can be cured and sight restored for those blinded by rare genetic disorders. How, in this time of such advancements, did we reach a point, where people cannot afford the very things that could save their lives? As the COVID-19 global pandemic has pointed out, we need the leadership of scientists, researchers, public health officials and lawmakers alike to guide us through not only in times of a global health crisis, but also during far more mundane times. For the first time in decades, people from all walks of life face the same need for medicine.  It is time to discuss the tough questions about drug pricing in an open, honest and, hopefully, transparent manner. But first we must understand how we, as a society, got here. Medicines are arguably the most highly regulated—and cost-inflated—products in the United States. The discovery, development, manufacturing and distribution of medicines is carried out by an ever more complex and crowded set of industries, each playing a part in a larger “pharmaceutical enterprise” seeking to maximize profits. But this was not always the case. The Price of Health is the reveals the story of how the pharmaceutical enterprise took shape and led to the present crisis. The reputation of the pharmaceutical industry is suffering from self-inflicted wounds and its continued viability, indeed survival, is increasingly questioned. Yet the drug makers do not shoulder all the blame or responsibility for the current price crisis. Deeply researched, The Price of Health gives us hope as to how we can still right the ship, even amidst the roiling storm of a global pandemic. How have medicines have been made and distributed to consumers throughout the years? What sea of changes that have contributed to rising costs? Some individuals, actions, and systems will be familiar, others may surprise. Yet the combined implications of these actions for will be surprising and at times shocking to both industry professionals and average Americans alike. Like so much else in human history, the history of the pharmaceutical enterprise is populated mostly by well-intended and even noble individuals and organizations. Each contributed to the formation or maintenance of structures meant to improve the quality and quantity of life through the development and distribution of medicines. And yet systems originally created to do good have often been subverted in ways contrary to the motivations of their creators. Only by understanding this disconnect can we better tackle the underlying problems of the industry head on, preventing foreseeable, and thus avoidable, medical calamities to come.

If you have a child in school, you may have heard stories of long-dormant diseases suddenly reappearing—cases of measles, mumps, rubella, and whooping cough cropping up everywhere from elementary schools to Ivy League universities because a select group of parents refuse to vaccinate their children. Between Hope and Fear tells the remarkable story of vaccine-preventable infectious diseases and their social and political implications. While detailing the history of vaccine invention, Kinch reveals the ominous reality that our victories against vaccine-preventable diseases are not permanent—and could easily be undone. In the tradition of John Barry’s The Great Influenza and Siddhartha Mukherjee’s The Emperor of All Maladies, Between Hope and Fear relates the remarkable intersection of science, technology and disease that has helped eradicate many of the deadliest plagues known to man.

The introduction of new medicines has dramatically improved the quantity and quality of individual and public health while contributing trillions of dollars to the global economy. In spite of these past successes — and indeed because of them — our ability to deliver new medicines may be quickly coming to an end. Moving from the beginning of the twentieth century to the present, A Prescription for Change reveals how changing business strategies combined with scientific hubris have altered the way new medicines are discovered, with dire implications for both health and the economy.To explain how we have arrived at this pivotal moment, Michael Kinch recounts the history of pharmaceutical and biotechnological advances in the twentieth century. Kinch relates stories of the individuals and organizations that built the modern infrastructure that supports the development of innovative new medicines. He shows that an accelerating cycle of acquisition and downsizing is cannibalizing that infrastructure Kinch demonstrates the dismantling of the pharmaceutical and biotechnological research and development enterprises could also provide opportunities to innovate new models that sustain and expand the introduction of newer and better breakthrough medicines in the years to come.

The introduction of new medicines has dramatically improved the quantity and quality of individual and public health while contributing trillions of dollars to the global economy. In spite of these past successes — and indeed because of them — our ability to deliver new medicines may be quickly coming to an end. Moving from the beginning of the twentieth century to the present, A Prescription for Change reveals how changing business strategies combined with scientific hubris have altered the way new medicines are discovered, with dire implications for both health and the economy.To explain how we have arrived at this pivotal moment, Michael Kinch recounts the history of pharmaceutical and biotechnological advances in the twentieth century. Kinch relates stories of the individuals and organizations that built the modern infrastructure that supports the development of innovative new medicines. He shows that an accelerating cycle of acquisition and downsizing is cannibalizing that infrastructure Kinch demonstrates the dismantling of the pharmaceutical and biotechnological research and development enterprises could also provide opportunities to innovate new models that sustain and expand the introduction of newer and better breakthrough medicines in the years to come.

A fascinating history of our understanding and the treatment of cancer by one of the leading figures in the field—who is also a pioneer on the cusp of a breakthrough.For the first time since a 5th century Greek physician gave the name “cancer” (karkinos, in Greek) to a deadly disease first described in Egyptian Papyri, the medical world is near a breakthrough that could allow even the most conservative doctors and pragmatic patients to use the other “c word” – cure – in the same sentence as cancer. A remarkable series of events has brought us to this point, thanks in large part to a new ability to more efficiently harness the extraordinary power of the human immune system. The End of the Beginning is a remarkable history of cancer treatment and the evolution of our understanding of its dynamic interplay with the immune system. Through Michael Kinch’s personal experience as a cancer researcher and the head of the oncology program at a leading biotechnology company, we witness the incredible accumulation of breakthrough science and its rapid translation into life-saving technologies that have begun to dramatically increase the quality and quantity of life for cancer patients. In clear and accessible prose, Kinch details the remarkable history of people, science, technology and disease and presents thrilling next-generation technologies that hold the promise to eliminate cancer for some, and perhaps ultimately, for all.